Barclays PLC Sponsored ADR logo

Barclays PLC Sponsored ADR (BCS)

Market Closed
15 Oct, 08:00 PM
NYSE NYSE
$
22. 81
+0.07
+0.3078%
$
77.38B Market Cap
- P/E Ratio
0.27% Div Yield
9.81M Volume
- Eps
$ 22.74
Previous Close
Add Transaction
Day Range
22.7 23.1
Year Range
19.29 28.69
Want to track BCS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
EU Banks Get Breathing Room as Capital Rule Decisions Face Delays

EU Banks Get Breathing Room as Capital Rule Decisions Face Delays

EU delays FRTB capital rules again, giving DB, BCS and BNPQY near-term relief while uncertainty lingers over Basel III rollout.

Zacks | 7 months ago
Barclays raises 2026 Brent forecast to $85 a barrel on Strait of Hormuz disruption

Barclays raises 2026 Brent forecast to $85 a barrel on Strait of Hormuz disruption

Barclays on Friday raised its 2026 Brent crude forecast to $85 per barrel, ​citing ongoing supply disruptions linked to the ‌Iran war that have sharply reduced oil flows through the Strait of Hormuz.

Reuters | 7 months ago
Just Buy It? Barclays Thinks Nike Is Ready to Run

Just Buy It? Barclays Thinks Nike Is Ready to Run

For months, investors have watched Nike, Inc. NYSE: NKE, a titan of the consumer discretionary world, struggle to find its footing, testing the patience of even its most loyal shareholders. The stock's persistent underperformance has been a key storyline.

Marketbeat | 7 months ago
Nike's Stock Gets an Upgrade. Barclays Says It's Likely Reached a 'Fundamental Bottom.

Nike's Stock Gets an Upgrade. Barclays Says It's Likely Reached a 'Fundamental Bottom.

Nike's stock could soon be due for a rebound, according to analysts at Barclays.

Investopedia | 7 months ago
Zealand Pharma A/S (ZLDPF) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Zealand Pharma A/S (ZLDPF) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Zealand Pharma A/S (ZLDPF) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Seekingalpha | 7 months ago
Tariff refunds are expected to come in the second quarter: Barclays

Tariff refunds are expected to come in the second quarter: Barclays

The Trump administration's new replacement tariffs could result in a lower effective rate of 9.1%, according to a strategist at J.P. Morgan Asset Management.

Marketwatch | 7 months ago
AI Disruption Fears Overdone, Says Barclays — Upgrades Arthur J. Gallagher and Willis Towers Watson

AI Disruption Fears Overdone, Says Barclays — Upgrades Arthur J. Gallagher and Willis Towers Watson

Barclays is pushing back against the narrative that artificial intelligence poses an existential threat to insurance brokers, upgrading two of the sector's largest names while trimming its price target on a third.

247wallst | 7 months ago
Elevance Health, Inc. (ELV) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Elevance Health, Inc. (ELV) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Elevance Health, Inc. (ELV) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Seekingalpha | 7 months ago
Barclays named a top global investment bank pick as JP Morgan says trading boom has further to run

Barclays named a top global investment bank pick as JP Morgan says trading boom has further to run

Analyst sees European banks closing valuation gap with Wall Street giants Goldman and Morgan Stanley Barclays PLC (LSE:BARC)  has been named a top pick among global investment banks by JP Morgan. It has upgraded its trading revenue forecasts across the sector after concluding that market volatility sparked by Middle East tensions will drive one of the strongest quarters for trading revenues on record.

Proactiveinvestors | 7 months ago
Barclays Stock Dips 14.1% YTD: Is It a Buy After the Recent Pullback?

Barclays Stock Dips 14.1% YTD: Is It a Buy After the Recent Pullback?

BCS stock has fallen 14.1% YTD amid volatility, but restructuring moves, acquisitions and plans to return 15B pounds to shareholders could support long-term growth.

Zacks | 7 months ago
Here's Why Barclays (BCS) is a Strong Value Stock

Here's Why Barclays (BCS) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 7 months ago
BCS or ITUB: Which Is the Better Value Stock Right Now?

BCS or ITUB: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Banks - Foreign sector might want to consider either Barclays (BCS) or Banco Itau (ITUB). But which of these two stocks presents investors with the better value opportunity right now?

Zacks | 7 months ago
Loading...
Load More